Scynexis (SCYX) Current Deferred Revenue (2013 - 2026)
Scynexis' (SCYX) quarterly Current Deferred Revenue came in at $235000.0 in Q1 2026, down 91.9% on a YoY basis from $2.9 million in Q1 2025, and little changed quarter-over-quarter from $235000.0 in Q4 2025.
Analysis
Scynexis (SCYX) Current Deferred Revenue (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Current Deferred Revenue for 11 consecutive years, with $235000.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue fell 91.9% year-over-year to $235000.0; the trailing twelve-month figure through Mar 2026 stood at $235000.0 (down 91.9% YoY), and the FY2025 full-year result was $235000.0, down 85.69% from the prior year.
- Current Deferred Revenue held at $235000.0 in Q1 2026 per SCYX's latest filing, from $235000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $3.2 million in Q2 2023 and bottomed at $235000.0 in Q4 2025.
- Historically, Current Deferred Revenue has averaged $1.7 million across 4 years, with a median of $1.6 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue jumped 163.64% in 2025, then slumped 91.9% in 2026.
- Over 4 years, Current Deferred Revenue stood at $1.2 million in 2023, then surged by 38.1% to $1.6 million in 2024, then slumped by 85.69% to $235000.0 in 2025, then changed by 0.0% to $235000.0 in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $235000.0, $235000.0, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 235,000.00 |
| Dec 31, 2025 | 235,000.00 |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 2.30 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 1.64 Mn |
| Sep 30, 2024 | 1.64 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | 1.19 Mn |
| Sep 30, 2023 | 2.44 Mn |
| Jun 30, 2023 | 3.23 Mn |
| Mar 31, 2019 | 54,000.00 |
| Dec 31, 2018 | 121,000.00 |
| Sep 30, 2018 | 185,000.00 |
| Jun 30, 2018 | 249,000.00 |
| Mar 31, 2018 | 257,000.00 |
| Dec 31, 2017 | 257,000.00 |
| Sep 30, 2017 | 257,000.00 |
| Jun 30, 2017 | 257,000.00 |